Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback